WASHINGTON — The Food and Drug Administration on Friday approved a new injectable drug to treat patients who have been exposed to the deadly toxin anthrax.
The FDA approved the drug called Anthim to treat inhalation anthrax, which can cause serious injury and death, and occurs when anthrax bacterial spores are inhaled. Because anthrax is a potential bioterrorism weapon the US government has been funding the development and production of therapies.
Anthim was developed by Elusys Therapeutics of Pine Brook, N.J., with support from the Biomedical Advanced Research and Development Authority.
